The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
Open accessAbstract
The effects of applying clinical versus neuropathological diagnosis and the inclusion of cases with coincident neuropathological diagnoses have not been assessed specifically when studying cerebrospinal fluid (CSF) biomarker classification cutoffs for patients with neurodegenerative diseases that cause dementia. Thus, 142 neuropathologically diagnosed neurodegenerative dementia patients [71 Alzheimer's disease (AD), 29 frontotemporal lobar degeneration (FTLD), 3 amyotrophic lateral sclerosis, 7 dementia with Lewy bodies, 32 of which cases also had coincident diagnoses] were studied. 96 % had enzyme-linked immunosorbant assay (ELISA) CSF data and 77 % had Luminex CSF data, with 43 and 46 controls for comparison, respectively. Aβ(42), total, and phosphorylated tau(181) were measured. Clinical and neuropathological diagnoses showed an 81.4 % overall agreement. Both assays showed high sensitivity and specificity to classify AD subjects against FTLD subjects and controls, and moderate sensitivity and specificity for classifying FTLD subjects against controls. However, among the cases with neuropathological diagnoses of AD plus another pathology (26.8 % of the sample), 69.4 % (ELISA) and 96.4 % (Luminex) were classified as AD according to their biomarker profiles. Use of clinical diagnosis instead of neuropathological diagnosis led to a 14-17 % underestimation of the biomarker accuracy. These results show that while CSF Aβ and tau assays are useful for diagnosis of AD and neurodegenerative diseases even at MCI stages, CSF diagnostic analyte panels that establish a positive diagnosis of Lewy body disease and FTLD are also needed, and must be established based on neuropathological rather than clinical diagnoses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As has been shown by Toledo et al., FTD biomarker studies can be confounded by AD co-pathology [91].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Winton, M. J., Lee, E. B., Sun, E., Wong, M. M., Leight, S., Zhang, B., Trojanowski, J., & Lee, V. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6637-10.2011 · Cited by 110
Self-citationRetractedModern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statisctics and computing/Statistics and computing · doi:10.1007/978-0-387-21706-2 · Cited by 25,941
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“CSF phosphorylated tau (p-tau) and total tau (t-tau) are also established AD biomarkers and both CSF tau and Ab have recently been added to the clinical diagnostic criteria for mild cognitive impairment (MCI) and AD [2, 11, 38].”
BackgroundBuilding Predictive Models in R Using the caret Package
Kuhn, M. (2008) · Journal of Statistical Software · doi:10.18637/jss.v028.i05 · Cited by 8,863
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Self-citationSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citation
Cited by
Sorted by citations
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationClinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,434
Self-citationToledo, J. B., Arnold, S. E., Raible, K., Brettschneider, J., Xie, S. X., Grossman, M., Monsell, S. E., Kukull, W. A., & Trojanowski, J. Q. (2013) · Brain · doi:10.1093/brain/awt188 · Cited by 849
Self-citationMetabolic network failures in Alzheimer's disease: A biochemical road map
Toledo, J. B., Arnold, M., Kastenmüller, G., Chang, R. R., Baillie, R., Han, X., Thambisetty, M., Tenenbaum, J. D., Suhre, K., Thompson, J. W., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.020 · Cited by 463
Self-citationComparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401
Self-citation
Metadata
- Authors
- Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q.
- Affiliations
- University of Pennsylvania (US)
- Emory University (US)
- Corresponding author
- Trojanowski, John Q.
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2012-04-22
- Volume
- 124
- Issue
- 1
- Pages
- 23-35
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC3551449
- OpenAlex
- W2022371215
- Cited by
- 182
- References
- 71
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 3 · 2022: 14 · 2021: 7 · 2020: 9 · 2019: 15 · 2018: 19 · 2017: 17 · 2016: 11 · 2015: 27 · 2014: 15 · 2013: 22 · 2012: 5
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health
- National Institute on Aging (AG15116, AG033101, P30AG010124, R01AG015116, P01AG017586, AG17586, AG-10124, K08AG033101)
- National Institute of Neurological Disorders and Stroke (P01NS044233, NS053488, NS-44266, P50NS053488, R01NS044266)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- cerebrospinal fluid biomarkers, Alzheimer's disease, frontotemporal lobar degeneration, dementia with Lewy bodies, amyotrophic lateral sclerosis, amyloid-beta 42, phosphorylated tau 181, diagnostic accuracy, neurodegenerative dementia, mild cognitive impairment, biomarker cut-off values
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Analysis of Variance, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Peptide Fragments, Psychiatric Status Rating Scales, Sensitivity and Specificity, Biomarkers, Amyloid beta-Peptides, tau Proteins, Area Under Curve, Frontotemporal Lobar Degeneration, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
